中国医学科学院学报2018，Vol.40Issue(1)：67-71,5.DOI:10.3881/j.issn.1000-503X.2018.01.010
超声引导下射频消融治疗甲状腺乳头状癌颈部转移淋巴结的疗效评价
Ultrasound-guided Radiofrequency Ablation for Cervical Lymph Nodes Metastasis from Papillary Thyroid Carcinoma
摘要
Abstract
Objective To assess the effectiveness and safety of ultrasound-guided percutaneous radiofrequency ablation (RFA) for nonsurgical treatment of metastatic lymph nodes (LNs) in the neck from papillary thyroid carcinoma (PTC).Methods Totally 45 PTC patients who had been treated with total thyroidectomy and radioiodine therapy were enrolled in this retrospective study.A total of 71 metastatic LNs in the neck from PTC were confirmed by percutaneous biopsy.Follow-up consisted of conventional ultrasound,contrast-enhanced ultrasound,and thyroglobulin (Tg) measurement 1,3 and 6 months after RFA and then every 6 months.Results All 45 patients were successfully treated,without immediate or later major complications occurred.During the follow-up [(23 ± 5) months;range:12-30 months)],there was no evidence of recurrence at ablated sites.The mean volume reduction ratio (VRR) was significantly reduced during the follow-up.Significant differences in the VRR were found between every two follow-up visits (P ＜ 0.001).Furthermore,46 metastatic LNs (64.8％) completely disappeared and 25 metastatic lymph nodes (35.2％) remained as small scar-like lesions at the last follow-up visit.After RFA,mean serum Tg level decreased from (11.3 ±6.3) ng/ml (range:0.8-19.4 ng/ml) to (1.3 ±0.9) ng/ml (range:0.2-3.9 ng/ml) at the last follow-up visit (P ＜0.001).Conclusion Ultrasound-guided percutaneous RFA is a safe and effective therapy for patients with cervical LNs metastasis from PTC.关键词
超声/射频消融/淋巴结/甲状腺乳头状癌Key words
ultrasound/radiofrequency ablation/lymph node/papillary thyroid carcinoma分类
医药卫生引用本文复制引用
广旸,罗渝昆,张艳,张明博,李楠,张颖,唐杰..超声引导下射频消融治疗甲状腺乳头状癌颈部转移淋巴结的疗效评价[J].中国医学科学院学报,2018,40(1):67-71,5.基金项目
国家自然科学基金(81471681)、北京市自然科学基金(15G30083)和中国人民解放军总医院临床科研扶持基金项目(2015PC-TSYS-2022)Supported by the National Natural Sciences Foundation of China(81471681),the Beijing National Science Foundation(15G30083) and the Clinical Research Support Foundation of PLA General Hospital (2015PC-TSYS-2022) （81471681）
